Filana Therapeutics, Inc. (FLNA) Balance Sheet
FLNA balance sheet, 2025
December 31, 2025 · U.S. dollars$118.4M assets = $44.0M liabilities + $74.4M equity
Both columns are drawn to the same scale: what FLNA owns equals what it owes plus shareholders’ equity. Hover a block for its value.
FLNA financial health
Descriptive bands, not a rating. Fiscal 2025.
FLNA balance sheet trends, 2022–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $234.8M2022 | $118.4M2025 | −20.4%/yr | |
| Total liabilities | $7.3M2022 | $44.0M2025 | +82.0%/yr | |
| Shareholders’ equity | $227.5M2022 | $74.4M2025 | −31.1%/yr | |
| Cash & short-term investments | $201.0M2022 | $95.5M2025 | −22.0%/yr | |
| Working capital | $204.2M2022 | $53.9M2025 | −$150.3M | |
| Book value per share | $5.662022 | $1.542025 | −35.2%/yr | |
| Current ratio | 29.912022 | 2.232025 | −27.68 | |
| Shares outstanding | 40.2M2022 | 48.3M2025 | +6.3%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
FLNA assets
FLNA liabilities and equity
FLNA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
FLNA balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | $95.5M | $128.6M | $121.1M | $201.0M |
| Cash & equivalents | $95.5M | $128.6M | $121.1M | $201.0M |
| Receivables | $120,000 | $947,000 | $962,000 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other current assets | $2.1M | $7.0M | $7.5M | $10.2M |
| Total current assets | $97.7M | $136.5M | $129.6M | $211.2M |
| Property, plant & equipment (net) | $20.6M | $21.0M | $21.9M | $23.0M |
| Goodwill & intangible assets | $0 | $37,000 | $176,000 | $622,000 |
| Long-term investments | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 |
| Total assets | $118.4M | $157.5M | $151.7M | $234.8M |
| Liabilities | ||||
| Accounts payable | $6.4M | $7.7M | $10.6M | $4.0M |
| Short-term debt | — | — | — | $104,000 |
| Total current liabilities | $43.8M | $11.8M | $14.2M | $7.1M |
| Long-term debt | $0 | $0 | $0 | $0 |
| Lease obligations | — | — | $0 | $139,000 |
| Other long-term liabilities | $117,999 | $79,000 | $0 | $232,000 |
| Total liabilities | $44.0M | $11.8M | $14.2M | $7.3M |
| Shareholders' equity | ||||
| Common stock & paid-in capital | $48,000 | $48,000 | $42,000 | $42,000 |
| Retained earnings (deficit) | −$496.1M | −$405.1M | −$380.8M | −$283.6M |
| Total shareholders' equity | $74.4M | $145.7M | $137.5M | $227.5M |
| Key figures | ||||
| Total debt | — | — | — | $139,000 |
| Net cash (debt) | — | — | — | $200.9M |
| Working capital | $53.9M | $124.8M | $115.4M | $204.2M |
| Tangible book value | $74.4M | $145.7M | $137.3M | $226.9M |
| Book value per share | $1.54 | — | $3.28 | $5.66 |
| Shares outstanding | 48.3M | — | 41.9M | 40.2M |
| Current ratio | 2.23 | 11.62 | 9.13 | 29.91 |
| Quick ratio | 2.18 | 11.02 | 8.60 | 28.46 |
| Debt / equity | — | — | — | 0.00 |
| Equity / assets | 62.9% | 92.5% | 90.6% | 96.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & short-term investments | $82.7M | $86.6M | $95.5M | $106.1M | $112.4M | $117.3M | $128.6M | $149.0M |
| Cash & equivalents | $82.7M | $86.6M | $95.5M | $106.1M | $112.4M | $117.3M | $128.6M | $149.0M |
| Receivables | $0 | $117,000 | $120,000 | $817,000 | $835,000 | $864,000 | $947,000 | $6.3M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $1.0M | $1.3M | $2.1M | $2.0M | $1.6M | $2.0M | $7.0M | $47.3M |
| Total current assets | $83.7M | $88.0M | $97.7M | $108.9M | $114.8M | $120.2M | $136.5M | $202.5M |
| Property, plant & equipment (net) | $20.2M | $20.4M | $20.6M | $20.8M | $20.6M | $20.8M | $21.0M | $21.1M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $37,000 | $69,000 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $103.9M | $108.4M | $118.4M | $129.7M | $135.4M | $140.9M | $157.5M | $223.8M |
| Liabilities | ||||||||
| Accounts payable | $39.3M | $39.2M | $6.4M | $46.1M | $42.8M | $8.2M | $7.7M | $52.2M |
| Total current liabilities | $40.2M | $40.1M | $43.8M | $48.0M | $47.3M | $13.2M | $11.8M | $57.0M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $135,999 | $110,999 | $117,999 | $119,000 | $79,000 | $79,000 | $79,000 | $80,000 |
| Total liabilities | $40.3M | $40.2M | $44.0M | $48.2M | $47.4M | $13.3M | $11.8M | $57.1M |
| Shareholders' equity | ||||||||
| Common stock & paid-in capital | $48,000 | $48,000 | $48,000 | $48,000 | $48,000 | $48,000 | $48,000 | $48,000 |
| Retained earnings (deficit) | −$515.0M | −$506.4M | −$496.1M | −$483.5M | −$472.7M | −$428.5M | −$405.1M | −$377.5M |
| Total shareholders' equity | $63.6M | $68.1M | $74.4M | $81.6M | $88.0M | $127.6M | $145.7M | $166.6M |
| Key figures | ||||||||
| Working capital | $43.6M | $47.8M | $53.9M | $60.9M | $67.5M | $106.9M | $124.8M | $145.5M |
| Tangible book value | $63.6M | $68.1M | $74.4M | $81.6M | $88.0M | $127.6M | $145.7M | $166.6M |
| Book value per share | $1.32 | $1.41 | $1.54 | $1.69 | $1.82 | $2.64 | — | $3.47 |
| Shares outstanding | 48.3M | 48.3M | 48.3M | 48.3M | 48.3M | 48.3M | — | 48.0M |
| Current ratio | 2.08 | 2.19 | 2.23 | 2.27 | 2.43 | 9.08 | 11.62 | 3.55 |
| Quick ratio | 2.06 | 2.16 | 2.18 | 2.22 | 2.39 | 8.93 | 11.02 | 2.72 |
| Equity / assets | 61.2% | 62.9% | 62.9% | 62.9% | 65.0% | 90.6% | 92.5% | 74.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 12, 2026); data from EODHD.
FLNA financial position
At the end of fiscal 2025 (December 31, 2025), Filana Therapeutics had total assets of $118.4 million (down 24.9% from a year earlier), total liabilities of $44.0 million and shareholders' equity of $74.4 million. Its current ratio was 2.23. In the latest quarter (ended June 30, 2026) total assets were $103.9 million and equity $63.6 million.
Related: FLNA income statement, FLNA cash flow statement, FLNA key metrics. See the FLNA stock overview for the latest quote and news.
FLNA balance sheet FAQ
What are Filana Therapeutics's total assets?
Filana Therapeutics reported total assets of $118.4 million at the end of fiscal 2025 (December 31, 2025), compared with $157.5 million a year earlier.
How much cash does Filana Therapeutics have?
Filana Therapeutics held $95.5 million in cash and short-term investments at the end of fiscal 2025.
What is Filana Therapeutics's book value?
Filana Therapeutics's shareholders' equity (book value) was $74.4 million at the end of fiscal 2025, or $1.54 per share.
What is Filana Therapeutics's current ratio?
Filana Therapeutics had current assets of $97.7 million and current liabilities of $43.8 million, a current ratio of 2.23 (it can cover its short-term obligations).